8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2010 / Randomized controlled trial
A randomized trial assigned 72 Danish children with autism spectrum disorders aged 4 to 10 years to a gluten- and casein-free diet or an unrestricted diet. At 12 months, evaluations of 26 diet-group participants and 29 controls revealed significant improvements in autism behaviors and hyperactivity scores. Group improvements were sustained through 24 months, although the absence of a placebo limits determining whether non-dietary factors contributed.
Whiteley P, Haracopos D, Knivsberg AM, et al. Nutr Neurosci, 2010. PMID 20406576
2010 / Randomized crossover trial
A randomized, double-blind crossover pilot trial evaluated 2 weeks of a tart cherry juice blend versus placebo in 15 older adults with chronic insomnia. Tart cherry juice significantly decreased minutes awake after sleep onset compared with placebo. However, it did not significantly improve sleep latency, total sleep time, or sleep efficiency relative to placebo, with overall effect sizes characterized as moderate to negligible.
Pigeon WR, Carr M, Gorman C, et al. J Med Food, 2010. PMID 20438325
2010 / Clinical trial
Researchers evaluated the effect of consuming seven different Jerte Valley cherry cultivars on the sleep-wake cycle, 6-sulfatoxymelatonin levels, and urinary total antioxidant capacity in middle-aged and elderly participants. Nocturnal activity and rest were measured by actigraphic monitoring. Intake of each cherry cultivar led to beneficial effects on actual sleep time, total nocturnal activity, assumed sleep, and immobility. Significant increases in urinary 6-sulfatoxymelatonin levels and total antioxidant capacity were also observed after intake of each cultivar.
Garrido M, Paredes SD, Cubero J, et al. J Gerontol A Biol Sci Med Sci, 2010. PMID 20547498
2010 / Randomized controlled trial
In a 16-week randomized, double-blind, placebo-controlled trial, 46 patients with mild to moderate Alzheimer's disease received 30 mg daily of saffron or a placebo. Saffron produced significantly better cognitive outcomes than placebo on the ADAS-cog scale (P = 0.04) and clinical dementia rating (P = 0.04). No significant differences between groups were observed for adverse events.
Akhondzadeh S, Sabet MS, Harirchian MH, et al. J Clin Pharm Ther, 2010. PMID 20831681
2010 / Randomized controlled trial
In a randomized trial, 168 older adults with mild cognitive impairment received daily B vitamins (0.8 mg folic acid, 0.5 mg B12, 20 mg B6) or placebo for 24 months. Brain atrophy averaged 0.76% per year in the active group versus 1.08% with placebo (P = 0.001). The response was greater among individuals with baseline homocysteine above 13 micromol/L, whose atrophy rate dropped by 53% (P = 0.001). Faster atrophy was linked to lower cognitive test scores.
Smith AD, Smith SM, de Jager CA, et al. PLoS One, 2010. PMID 20838622
2010 / Double-blind, multicenter, randomized controlled trial
In the DOMInO trial, 2399 pregnant women were randomized to receive 800 mg/d DHA via fish oil capsules or matched vegetable oil capsules without DHA until birth. High postpartum depressive symptoms occurred in 9.67% of women in the DHA group and 11.19% in the control group (adjusted RR, 0.85; 95% CI, 0.70-1.02; P = .09). Among children followed at 18 months, mean cognitive composite scores (adjusted mean difference, 0.01; 95% CI, -1.36 to 1.37; P = .99) and mean language composite scores (adjusted mean difference, -1.42; 95% CI, -3.07 to 0.22; P = .09) did not differ significantly between groups.
Makrides M, Gibson RA, McPhee AJ, et al. JAMA, 2010. PMID 20959577
2009 / Double-blind, placebo-controlled study
Sixteen healthy participants were evaluated in a double-blind, placebo-controlled study using a gelatin-based protein drink to induce acute tryptophan depletion (ATD). Plasma tryptophan ratio significantly decreased following ATD and did not significantly increase in the placebo condition. Following ATD, delayed recall in the verbal learning test and delayed relocation of objects in the spatial task were impaired, whereas spatial short-term memory improved.
Sambeth A, Riedel WJ, Tillie DE, et al. J Psychopharmacol, 2009. PMID 18515454
2009 / Double-blind, parallel-group, placebo-controlled randomized trial
Thirty Japanese men and women aged 50 to 80 with mild cognitive impairment were randomized to take either Yamabushitake (four 250 mg tablets containing 96% dry powder three times daily) or placebo for 16 weeks, followed by 4 weeks of observation. At weeks 8, 12, and 16, the Yamabushitake group showed significantly increased cognitive function scale scores compared with placebo, with scores increasing with duration of intake. However, scores decreased significantly by 4 weeks after terminating intake. Laboratory tests showed no adverse effects.
Mori K, Inatomi S, Ouchi K, et al. Phytother Res, 2009. PMID 18844328
2009 / Randomized controlled trial
Sixty-two women attempting to lose weight were randomized to four 2-hour mindfulness workshops or a control condition continuing normal diets, with data collected at baseline, 4, and 6 months. At 6 months, intervention participants had significantly greater increases in physical activity versus controls (p<.05), but no significant differences in weight loss or mental health. When excluding participants who reported 'never' applying workshop principles (n=7), the intervention group showed significantly greater increases in physical activity (3.1 sessions per week relative to controls, p<.05) and significantly greater reductions in BMI (0.96 relative to controls, equivalent to 2.32 kg, p<0.5). Reductions in BMI were mediated primarily by reductions in binge eating.
Tapper K, Shaw C, Ilsley J, et al. Appetite, 2009. PMID 19101598
2009 / Randomized, double-blind, placebo-controlled pilot study
In this pilot study, 39 chronic fatigue syndrome patients were randomized to receive either 24 billion colony forming units of Lactobacillus casei strain Shirota (LcS) or a placebo daily for two months. Patients provided stool samples and completed the Beck Depression and Beck Anxiety Inventories before and after treatment. There was a significant rise in both Lactobacillus and Bifidobacteria in the LcS group, along with a significant decrease in anxiety symptoms compared to controls (p = 0.01).
Rao AV, Bested AC, Beaulne TM, et al. Gut Pathog, 2009. PMID 19338686
2009 / Double-blind randomized placebo-controlled trial
A 12-week randomized trial evaluated 93 post-menopausal women receiving either 20 g soy protein with 160 mg total isoflavones or a taste-matched whole milk protein placebo. Eighty-four women completed the study. Women taking isoflavones experienced significant improvements in all four Menopause-specific Quality of Life subscales (vasomotor, psychosexual, physical, and sexual), with no changes in the placebo group. No significant changes occurred within groups for cognition, serum androgens, or plasma lipids, though a group-by-time interaction showed significantly lower total testosterone and HDL levels in the isoflavone group versus placebo at study end.
Basaria S, Wisniewski A, Dupree K, et al. J Endocrinol Invest, 2009. PMID 19411814
2009 / Randomized controlled trial (substudy)
In a substudy of the Women's Antioxidant Cardiovascular Study, 2,824 women aged >=65 years were tested 4 times over 5.4 years to evaluate the effects of vitamin E (402 mg alternate days), beta carotene (50 mg alternate days), and vitamin C (500 mg daily). Vitamin E and beta carotene were not associated with slower rates of cognitive change compared to placebo (mean difference in change: -0.01, 95% CI -0.05 to 0.04, P=0.78 for vitamin E; 0.03, 95% CI -0.02 to 0.07, P=0.28 for beta carotene). Vitamin C was associated with better performance at the final assessment (mean difference 0.13, 95% CI 0.06 to 0.20, P=0.0005) but was not associated with cognitive change over time (mean difference 0.02, 95% CI -0.03 to 0.07, P=0.39).
Kang JH, Cook NR, Manson JE, et al. Circulation, 2009. PMID 19451353
2009 / Randomized controlled trial
Fifty-seven Alzheimer's disease patients were randomized to receive placebo or 800 IU of vitamin E daily for six months, with 33 finishing the trial. Among vitamin E-treated patients, respondents showed lower blood oxidized glutathione (GSSG) levels and maintained cognitive test scores. In non-respondents where oxidative stress was not prevented, cognition decreased sharply to levels lower than those taking placebo.
Lloret A, Badía MC, Mora NJ, et al. J Alzheimers Dis, 2009. PMID 19494439
2009 / Randomized controlled trial
Fifty-eight children aged 7 to 9 years were randomly assigned to drink additional water or receive no extra water. Children who consumed extra water rated themselves as significantly less thirsty (p = 0.002). They also scored significantly better on visual attention tasks, including letter cancellation (p = 0.02) and spot-the-difference memory tests (p = 0.019 and p = 0.014).
Edmonds CJ, Burford D Appetite, 2009. PMID 19501780
2009 / Randomized, double-blind, placebo-controlled trial
A 90-day randomized, double-blind, placebo-controlled trial evaluated daily administration of the ketogenic compound AC-1202 in 152 patients with mild to moderate Alzheimer's disease who maintained a normal diet. AC-1202 significantly elevated serum beta-hydroxybutyrate 2 hours post-dose. Compared to placebo, AC-1202 led to a significant difference in mean change from baseline in ADAS-Cog score at Day 45 across the ITT (1.9-point difference, p = 0.0235), per-protocol (2.53-point difference, p = 0.0324), and dosage-compliant (2.6-point difference, p = 0.0215) groups. Improvements were most pronounced in APOE4-negative subjects, showing significant ADAS-Cog differences at both Day 45 and Day 90. Adverse events were more frequent with AC-1202, primarily mild-to-moderate and transient gastrointestinal issues.
Henderson ST, Vogel JL, Barr LJ, et al. Nutr Metab (Lond), 2009. PMID 19664276
2009 / Intervention trial
Researchers evaluated whether drinking water improved performance from baseline to test in twenty-three 6-7-year-old children assigned to a water or no-water group. Significant interactions were observed between test time and water group, showing improvements in the water group for thirst, happiness ratings, visual attention, and visual search. However, no improvements were seen for visual memory or visuomotor performance.
Edmonds CJ, Jeffes B Appetite, 2009. PMID 19835921
2009 / Randomized controlled trial
Researchers randomized 106 overweight and obese adults to an energy-restricted low-carbohydrate or low-fat diet for one year. Both groups achieved similar average weight loss (13.7 kg overall, P = .26) and working memory improvements. However, the low-fat diet led to significantly greater improvements in anxiety, depression, anger, confusion, and total mood disturbance scores compared with the low-carbohydrate diet (P < .05).
Brinkworth GD, Buckley JD, Noakes M, et al. Arch Intern Med, 2009. PMID 19901139
2009 / Placebo-controlled, double-blind trial
A double-blind, placebo-controlled study evaluated the effects of 250 mg or 500 mg daily of BETA 1,3/1,6 GLUCAN compared to placebo over a 4-week post-marathon period in 75 runners. Participants completed the Profile of Mood State (POMS) assessment and a health log measuring URTI symptoms at 2 and 4 weeks. Over the 4-week study, subjects taking either dose of beta-glucan reported significantly fewer URTI symptoms, better overall health, decreased confusion, fatigue, tension, and anger, and increased vigor compared to placebo.
Talbott S, Talbott J J Sports Sci Med, 2009. PMID 24149590
2008 / Randomized crossover imaging trial
Researchers assessed taste pleasantness across a concentration gradient and measured brain responses via functional MRI during administration of 10% sucrose and matched sucralose in 12 healthy women. Both sweeteners activated functionally connected primary taste pathways, and taste pleasantness predicted left insula response. However, sucrose elicited a stronger brain response than sucralose in the anterior insula, frontal operculum, striatum, and anterior cingulate. Additionally, only sucrose stimulation engaged dopaminergic midbrain areas in relation to behavioral pleasantness.
Frank GK, Oberndorfer TA, Simmons AN, et al. Neuroimage, 2008. PMID 18096409
2008 / Double-blind, randomised and placebo-controlled trial
A double-blind, randomized, placebo-controlled trial evaluated whether saffron (30 mg/day; 15 mg twice a day) relieved premenstrual syndrome (PMS) symptoms compared to placebo across two menstrual cycles (cycles 3 and 4) in women aged 20-45 years. Saffron was found to be effective in relieving PMS symptoms. A significant difference was observed in efficacy of saffron in cycles 3 and 4 in the Total Premenstrual Daily Symptoms and the Hamilton Depression Rating Scale.
Agha-Hosseini M, Kashani L, Aleyaseen A, et al. BJOG, 2008. PMID 18271889
2008 / Randomized controlled trial
Researchers evaluated the effect of a realistic dietary dose of L-theanine (50mg) versus placebo on brain function. EEG was recorded in healthy, young participants resting with eyes closed at baseline and 45, 60, 75, 90, and 105 minutes after ingestion (L-theanine n=16, placebo n=19). There was a greater increase in alpha activity across time in the L-theanine condition relative to placebo (p+0.05 [sic]). A second study replicated this effect in participants engaged in passive activity.
Nobre AC, Rao A, Owen GN Asia Pac J Clin Nutr, 2008. PMID 18296328
2008 / Double-blind, randomized, controlled clinical trial
A double-blind trial evaluated the effects of 50 mg daily oral DHEA versus placebo for 1 year in 225 healthy older adults. There were no differences between the DHEA and placebo groups in change over time in cognitive function (P > .10). Over time, BDI scores decreased for men (P = .006) and women (P = .02), and Satisfaction with Life Scale scores increased for women (P = .004), but no differences were observed between the DHEA and placebo groups on these measures, the SF-36, the Life Satisfaction Index-Z scale, or sexual function scales (P > .10).
Kritz-Silverstein D, von Mühlen D, Laughlin GA, et al. J Am Geriatr Soc, 2008. PMID 18482290
2008 / Randomized, double-blind, placebo-controlled crossover trial
Fourteen postmenopausal women completed a randomized, double-blind, placebo-controlled crossover trial receiving 3.5 g/day of powdered Maca and matching placebo for 6 weeks each. No significant differences were observed in serum concentrations of estradiol, FSH, LH, or SHBG between baseline, Maca, and placebo (P > 0.05). However, Maca significantly reduced Greene Climacteric Scale scores for psychological symptoms, including anxiety, depression, and sexual dysfunction compared to baseline and placebo (P < 0.05). Yeast-based assays showed no physiologically significant estrogenic or androgenic activity in Maca extracts.
Brooks NA, Wilcox G, Walker KZ, et al. Menopause, 2008. PMID 18784609
2008 / Double-blind, randomized, parallel-group pilot dose-finding trial
A double-blind pilot study evaluated low-dose (1.5 g/day) versus high-dose (3.0 g/day) maca in 20 remitted depressed outpatients with SSRI-induced sexual dysfunction. In intent-to-treat analyses, subjects on 3.0 g/day showed significant improvements in ASEX scores (from 22.8 +/- 3.8 to 16.9 +/- 6.2; P=0.028) and MGH-SFQ scores (from 24.1 +/- 1.9 to 17.0 +/- 5.7; P=0.017), while those on 1.5 g/day did not. Libido improved significantly based on ASEX item #1 for the ITT and completer groups (P<0.05), but not when analyzed by dosing groups. Maca was well tolerated.
Dording CM, Fisher L, Papakostas G, et al. CNS Neurosci Ther, 2008. PMID 18801111